Efficacy of Direct-acting Antivirals in Hemodialysis Patients with Chronic Hepatitis C: A Real-life Retrospective Study
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 3
Abstract
Objectives: Hepatitis C virus (HCV) infection is common among hemodialysis (HD) patients and is associated with increased morbidity and mortality. New generation direct-acting antiviral (DAA) agents are safe and effective in treatment HCV infection in HD patients. The aim of this a multi-center study was to assess the efficacy of DAAs in HD patients with HCV infection. Materials and Methods: HD patients with HCV infection followedup at five centers were included in this retrospective cohort study. Patients demographic and virological characteristics, liver fibrosis status, end of treatment and sustained virologic responses (SVR12) at 12 weeks after treatment were recorded. Treatment of the patients was arranged according to the genotype and drug interactions considering guidelines. Results: Ninety percent of 20 patients were genotype 1b and were treated for 12 weeks with paritaprevir-ritonavir-ombitasvir-dasabuvir; one patient was genotype 4 and received PrOD + ribavirin (RBV) for 12 weeks; and one patient was genotype 3 and was treated with sofosbuvir + RBV for 24 weeks. HCV-RNA negativity was achieved in all patients at the end of treatment and SVR12 rate was 100%. Significant side effects were not observed in any patients, apart from sleeplessness in one patient and itching in another. Conclusion: Our real-life data support that new generation DAAs achieve high SVR and are well tolerated in HD patients with HCV. In these patients, intolerance and side effects were not observed, which would otherwise require cessation of the DAA regimen.
Authors and Affiliations
Nurten Nur Aydın, Firdevs Aksoy, İlknur Yavuz, Serap İskender, Arzu Altunçekiç Yıldırım, İlknur Esen Yıldız, İftihar Köksal
Keywords
Related Articles
- EP ID EP676548
- DOI 10.4274/vhd.galenos.2019.2019.0025
- Views 192
- Downloads 0
Comparison of Liver Histopathology with Non-invasive Inflammation Markers as Neutrophil-lymphocyte Ratio, Platelet-lymphocyte Ratio and Mean Platelet Volume in Chronic Hepatitis B Patients
Objectives: Platelet-lymphocyte ratio (PLR) and neutrophillymphocyte ratio (NLR) are commonly studied non-invasive inflammatory markers in cancer patients. There are some studies showing its association with fibrosis in...
The Evaluation of a Hundred Eleven Adult Patients with Acute Hepatitis
Objectives: We aimed to evaluate the etiological, epidemiological and laboratory characteristics of adult patients admitted to our hospital with acute hepatitis. Materials and Methods: The patients with alanine aminotra...
The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Material...
Examination of Mutations in the HBsAg and Polymerase Genes Induced by Pegylated Interferon Alpha and Oral Antivirals Used in the Treatment of Chronic Hepatitis B
Objectives: The Hepatitis B Virus is a virus having high mutation frequency due to having a high replication capacity and not having error correction capability in reverse transcription.It is aimed to examine the mutatio...
Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection
Objectives: This study aimed to investigate the effect of treatment with direct-acting antivirals (DAAs) on the virological response and on the some parameters used to evaluate liver function in cases with chronic liver...